ID
32063
Beskrivning
Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form is for documentation of medical history and results of the physical examination. To be assessed at visit 1. Timing: Day 0 Age: 6 weeks +/- 1 week
Länk
https://clinicaltrials.gov/ct2/show/NCT00139334
Nyckelord
Versioner (2)
- 2018-10-16 2018-10-16 - Sarah Riepenhausen
- 2018-10-16 2018-10-16 - Sarah Riepenhausen
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
16 oktober 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
GSK Biologicals' oral HRV vaccine given with OPV in infants NCT00139334
Medical history and Physical examination
- StudyEvent: ODM
Similar models
Medical history and Physical examination
- StudyEvent: ODM
C0031809 (UMLS CUI-2)
C0262926 (UMLS CUI [1,2])
C1457887 (UMLS CUI [2,1])
C0262926 (UMLS CUI [2,2])
C0205394 (UMLS CUI [1,2])
C0679831 (UMLS CUI [1,2])
C0521116 (UMLS CUI [1,2])